Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on June 5, 2025. The report details the outcomes of the Company's 2025 Annual Meeting of Stockholders held on the same date and the subsequent reconstitution of Board committees effective immediately following the meeting.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results rather than financial performance.
Material Changes and Governance Updates
Following the Annual Meeting, the Board reconstituted its committees with the following composition:
- Audit Committee: Kim Keck (Chair), Shawn Guertin, Brendan Springstubb.
- Compensation Committee: Peter Grua (Chair), Richard Jelinek, Cheryl Scott, Brendan Springstubb.
- Nominating and Governance Committee: Cheryl Scott (Chair), Russell Glass, Kim Keck.
- Compliance and Regulatory Affairs Committee: Toyin Ajayi, MD (Chair), Craig Barbarosh, Russell Glass.
- Strategy Committee: Craig Barbarosh (Chair), Toyin Ajayi, MD, Richard Jelinek, Brendan Springstubb.
Notably, Brendan Springstubb was appointed to both the Audit and Compensation Committees, fulfilling an agreement made in February 2025 with Engaged Capital, LLC.
Voting Results and Management Commentary
Stockholders voted on four proposals at the 2025 Annual Meeting. All proposals were approved:
- Proposal 1 (Election of Directors): All ten nominees were elected. While most received over 85% support, Peter Grua and Kim Keck received approximately 86% and 85% "For" votes respectively, with higher "Against" votes compared to other nominees.
- Proposal 2 (Ratification of Auditors): Deloitte & Touche LLP was ratified with 98% "For" votes (100,396,561 For vs. 21,620 Against).
- Proposal 3 (Say-on-Pay): Executive compensation for 2024 was approved with approximately 88% "For" votes (77,588,031 For vs. 10,172,695 Against).
- Proposal 4 (Incentive Plan Amendment): The amendment to the 2015 Omnibus Incentive Compensation Plan was approved with approximately 96% "For" votes (84,769,019 For vs. 3,033,271 Against).
Investor Verification Checklist
- Verify the specific terms of the Cooperation Agreement with Engaged Capital, LLC referenced in the Prior 8-K (February 4, 2025) to understand the context of Brendan Springstubb's committee appointments.
- Review the definitive proxy statement (Schedule 14A) filed on April 25, 2025, for detailed biographies of the elected directors and the specifics of the Incentive Plan amendment.
- Monitor future filings for the Company's next quarterly or annual report to obtain the missing financial metrics (revenue, profit, cash flow) not included in this 8-K.
- Assess the significance of the "Against" votes for directors Peter Grua and Kim Keck relative to the total votes cast to gauge shareholder sentiment.